New Oral Drug Zuranolone (Zurzuvae) for Postpartum Depression is Now Available
The FDA approves zuranolone, a new option for the treatment of PPD, a rapidly acting antidepressant with a good safety profile.
New Oral PPD Treatment Zuranolone Will Soon Hit the Market as Zurzuvae
The FDA approves zuranolone, a new option for the treatment of PPD, a rapidly acting antidepressant with a good safety profile.
FDA Approves Zuranolone for the Treatment of Postpartum Depression
The FDA approves zuranolone, a new option for the treatment of PPD, a rapidly acting antidepressant with a good safety profile.
More Data on Zuranolone for Postpartum Depression: When Will It Hit the Market?
In women with severe postpartum depression, zuranolone was associated with improvements in depression beginning at day 3. FDA to make a decision next week.
Recruiting for Research Study: Pregnenolone Neurosteroid for Menopausal Depression
As of October 2023, the Neurosteroid Intervention for Menopausal and Perimenopausal Depression is no longer recruiting participants. Over the last few years we have heard a great deal about neurosteroids, also known as neuroactive steroids. [...]
Zuranolone Improves Anxiety Symptoms and Insomnia in Women with Postpartum Depression
In women with postpartum depression, zuranolone was associated with concurrent improvements in depression, anxiety symptoms, and insomnia beginning at day 3.
New Research Study at the CWMH: A Novel Treatment for Menopausal Depression
The transition to menopause, or perimenopause, represents the passage from reproductive to non-reproductive life. During the perimenopause, women experience irregular menstrual cycles, which reflect the large fluctuations in ovarian hormone [...]
Essential Reads: Neurosteroids, Allopregnanolone and Vulnerability to Depression in Women
This article focuses on how GABA-ergic neurotransmitter systems may modulate the interaction between reproductive steroid and sex steroid systems, and sheds light on the role allopregnanolone may play in medicating vulnerability to depression.Â
More Data on the Neuroactive Steroid Zuranolone for Postpartum Depression
While we have heard a lot about brexanolone, marketed by Sage Therapeutics as Zulresso, for the treatment of postpartum depression, an oral version of this novel antidepressant – SAGE 217 or zuranolone – has been [...]
Pilot Study of Neurosteroid Ganaxolone for Menopausal Depression
Over the last few years we have heard a great deal about neurosteroids, also known as neuroactive steroids. This class of compounds are steroid hormones produced in the brain and endocrine tissues which can modulate [...]